美国食品药品监督管理局（FDA）已正式认可，由Disc Medicine公司开展的Aurora及Beacon临床试验所提交的数据充分证明，其在研药物Bitopertin能够显著降低患者血液中的原卟啉（Ppix）水平。这一关键进展为Bitopertin的后续开发及潜在获批奠定了重要基础。
美国食品药品监督管理局（FDA）已正式认可，由Disc Medicine公司开展的Aurora及Beacon临床试验所提交的数据充分证明，其在研药物Bitopertin能够显著降低患者血液中的原卟啉（Ppix）水平。这一关键进展为Bitopertin的后续开发及潜在获批奠定了重要基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.